WASHINGTON — For seventy years the question of which American scientists get federal money has been answered, in the main, by other scientists. A proposed White House rule would change that answer to: whoever the president has put in charge. A 412-page proposal issued by the Office of Management and Budget would give political appointees the final say over federal research grants and demote the scientific peer review that has underpinned American discovery to the status of advice the government may take or leave. It is the most sweeping attempt to politicize the machinery of US science funding in living memory, and it is happening now, in an open comment period, while researchers race to stop it.
The core of the plan is a single, consequential move. As Axios reported when the proposal landed, it would require a political appointee to perform a “pre-issuance review” of discretionary grants to confirm they advance the president’s policy priorities before any money goes out. Peer review by program officers and outside scientists, the gold standard for judging whether research is sound, would become merely advisory. The expertise stays in the room; the decision leaves it.
It does not stop at approvals. As CNN detailed, the rule would formally ban research touching on diversity, equity and inclusion or on gender as a condition of funding, and it would prohibit federally funded US scientists from collaborating with colleagues abroad. Grant holders would need agency sign-off, written into the award, simply to attend a conference. Federal support for publishing results in scientific journals would be restricted. And agencies would gain explicit authority to terminate or suspend active grants whenever an award is deemed to “no longer advance agency priorities or the national interest” — language broad enough to end almost any project a new appointee dislikes.
The administration frames all of this as housekeeping. OMB says the overhaul, which applies to every federal agency that hands out money, is meant to “improve transparency, accountability, and oversight” of taxpayer funds, and there is a narrow case to be made that grant-making can always be run more cleanly. But transparency does not require that a political appointee hold a veto over which cancer study or climate model the government is willing to pay for. Oversight does not demand that American scientists be walled off from the rest of the world. The stated goal and the actual mechanism do not match, and the gap between them is where the politics lives.
Scientists who have read the document are blunt about what it builds. Elizabeth Ginexi, a former NIH program official, called it “a complete political control apparatus layered over every stage of the federal science funding lifecycle.” That is the worry in one sentence: not that any single grant is at risk, but that the criterion for funding shifts from whether the science is good to whether it pleases the people in power. Peer review is slow and imperfect, but it is the reason American laboratories have led the world for generations. Replacing scientific merit with political loyalty as the deciding test does not make the system more accountable. It makes it answerable to a different master.
None of it arrives in a vacuum. The proposal is the formal, permanent version of a campaign the administration has been waging piecemeal since January. A federal judge has already ruled that the administration’s earlier directives canceling NIH grants were “void” and “illegal,” and as NBC News has documented, both courts and Congress have repeatedly rebuffed the White House’s attempts to claw back research money. The administration fired all twenty-two members of the National Science Board, scrapped roughly a billion dollars in NSF grants, and froze billions in funding to universities like Harvard. It has bent public health to ideology, installing an apparatus that let officials rewrite the vaccine schedule over scientific objection. The grant rule would lock all of that in.
The cost will not be obvious at first, because lost science is invisible: the treatment that was never developed, the discovery that went to a laboratory in another country, the young researcher who decided the United States was no longer the place to build a career. The ban on international collaboration alone would isolate American science from the global networks that produce most modern breakthroughs. It is of a piece with the broader hollowing-out of federal expertise that has left agency after agency short of the people who know how to do the work.
The proposal is open for public comment now, and researchers, universities, scientific journals and medical societies are flooding the docket in an effort to force a retreat. Whether they succeed or not, the document has already made the administration’s intention explicit. It says the goal is better oversight of public money. What it actually installs is a rule that the science the government funds must first serve the president. That is not accountability to the public. It is the opposite, and it is the point.
